{"news_desk": "Business", "print_page": null, "section_name": "Business Day", "subsection_name": "DealBook", "byline": {"original": "By ROBERT CYRAN", "person": [{"rank": 1, "role": "reported", "firstname": "Robert", "organization": "", "lastname": "CYRAN"}]}, "abstract": null, "type_of_material": "News", "word_count": "378", "lead_paragraph": "With the sale of Par Pharmaceutical, the buyout firm will generate an eightfold return on its investment in three years.", "pub_date": "2015-05-19T00:00:00Z", "document_type": "article", "slideshow_credits": null, "headline": {"main": "TPG\u2019s $8 Billion Drug Sale a Rare Development", "content_kicker": "Breakingviews", "kicker": "Breakingviews"}, "snippet": "With the sale of Par Pharmaceutical, the buyout firm will generate an eightfold return on its investment in three years.", "multimedia": [], "web_url": "http://www.nytimes.com/2015/05/19/business/dealbook/tpgs-8-billion-drug-sale-a-rare-development.html", "keywords": [{"rank": "1", "is_major": "N", "value": "Mergers, Acquisitions and Divestitures", "name": "subject"}, {"rank": "2", "is_major": "N", "value": "Endo International PLC", "name": "organizations"}, {"rank": "3", "is_major": "N", "value": "Par Pharmaceutical Cos Inc", "name": "organizations"}, {"rank": "4", "is_major": "N", "value": "TPG Capital", "name": "organizations"}, {"rank": "5", "is_major": "N", "value": "Bonderman, David", "name": "persons"}, {"rank": "6", "is_major": "N", "value": "Drugs (Pharmaceuticals)", "name": "subject"}], "blog": [], "_id": "555a34b038f0d803a0965b90", "source": "The New York Times"}